liver tumor tissues; adjacent non-tumorous tissues; tumor tissues
HepG2.2.15; Hep3B; HepG2; Huh7
cell line-derived xenograft
viral replication (promotes); proliferation (promotes); migration (promotes); invasion (promotes); apoptosis (inhibits); ceRNA regulation (other); EMT (promotes)
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; RT-qPCR; Clinical Sample Validation; Transfection; CCK8; Colony Formation Assay; EdU Staining; Annexin V/PI Flow Cytometry; Transwell Assay; Wound Healing Assay; Nuclear-Cytoplasmic Fractionation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; IF (Immunofluorescence); ELISA; Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model; Bioinformatics Analysis
Targeting circBRWD1 may offer a novel therapeutic strategy for HBV-related HCC and potentially address HBV persistence.
circBRWD1 is overexpressed in HBV-positive HCC tissues and cells and functions as an oncogenic circRNA. It promotes HBV replication, cccDNA accumulation, tumor cell proliferation, migration, invasion, and in vivo tumor growth while suppressing apoptosis. Mechanistically, circBRWD1 sponges miR-513a-5p to upregulate TNPO1, forming a circBRWD1/miR-513a-5p/TNPO1 regulatory axis.
0.869
CircBRWD1 promotes hepatitis B virus replication and hepatocellular carcinoma progression by regulating the miR-513a-5p/TNPO1 axis.
combined biological and clinical study